FY2026 Earnings Forecast for TLSI Issued By Northland Capmk

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Equities research analysts at Northland Capmk lifted their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a report issued on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of ($0.60) for the year, up from their prior forecast of ($0.75). Northland Capmk currently has a “Strong-Buy” rating on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

A number of other research firms also recently weighed in on TLSI. Canaccord Genuity Group reduced their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Oppenheimer began coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company. Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Finally, Roth Mkm began coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price objective for the company. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $12.08.

TriSalus Life Sciences Stock Up 7.3 %

Shares of TLSI stock opened at $4.56 on Thursday. The stock has a market cap of $139.05 million, a price-to-earnings ratio of -1.83 and a beta of 0.49. The business’s fifty day moving average is $4.23 and its 200 day moving average is $5.43. TriSalus Life Sciences has a twelve month low of $3.61 and a twelve month high of $10.42.

Institutional Trading of TriSalus Life Sciences

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences during the third quarter valued at approximately $92,000. Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. Vestcor Inc purchased a new stake in TriSalus Life Sciences during the 3rd quarter valued at $108,000. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at $184,000. Finally, Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth $66,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Insider Buying and Selling

In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 7,520 shares of TriSalus Life Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This represents a 2.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders bought a total of 19,560 shares of company stock worth $95,190 in the last three months. Insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.